Cargando…

Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy

TAS-102, with its robust survival efficacy and feasible toxicity, is one of the standard salvage-line treatments for patients with metastatic colorectal cancer (mCRC). No definitive data are available to determine which drug should be administered first during salvage-line treatment. Therefore, it i...

Descripción completa

Detalles Bibliográficos
Autores principales: Sunakawa, Yu, Izawa, Naoki, Mizukami, Takuro, Horie, Yoshiki, Hirakawa, Mami, Arai, Hiroyuki, Ogura, Takashi, Tsuda, Takashi, Nakajima, Takako Eguchi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608085/
https://www.ncbi.nlm.nih.gov/pubmed/28979148
http://dx.doi.org/10.2147/OTT.S106101
_version_ 1783265382502498304
author Sunakawa, Yu
Izawa, Naoki
Mizukami, Takuro
Horie, Yoshiki
Hirakawa, Mami
Arai, Hiroyuki
Ogura, Takashi
Tsuda, Takashi
Nakajima, Takako Eguchi
author_facet Sunakawa, Yu
Izawa, Naoki
Mizukami, Takuro
Horie, Yoshiki
Hirakawa, Mami
Arai, Hiroyuki
Ogura, Takashi
Tsuda, Takashi
Nakajima, Takako Eguchi
author_sort Sunakawa, Yu
collection PubMed
description TAS-102, with its robust survival efficacy and feasible toxicity, is one of the standard salvage-line treatments for patients with metastatic colorectal cancer (mCRC). No definitive data are available to determine which drug should be administered first during salvage-line treatment. Therefore, it is imperative that we establish the sequence of administration by considering drug toxicity profiles based on patient characteristics, such as age, performance status, comorbidities, tolerability to previous treatments, and patient preferences. The identification of predictive biomarkers in response to TAS-102 or its toxicity is urgently needed for better patient selection. Moreover, to strengthen efficacy or relieve toxicity, combinations with other agents, which could potentially emerge as standard treatment regimens, have been investigated and compared to existing active regimens for mCRC.
format Online
Article
Text
id pubmed-5608085
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-56080852017-10-04 Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy Sunakawa, Yu Izawa, Naoki Mizukami, Takuro Horie, Yoshiki Hirakawa, Mami Arai, Hiroyuki Ogura, Takashi Tsuda, Takashi Nakajima, Takako Eguchi Onco Targets Ther Review TAS-102, with its robust survival efficacy and feasible toxicity, is one of the standard salvage-line treatments for patients with metastatic colorectal cancer (mCRC). No definitive data are available to determine which drug should be administered first during salvage-line treatment. Therefore, it is imperative that we establish the sequence of administration by considering drug toxicity profiles based on patient characteristics, such as age, performance status, comorbidities, tolerability to previous treatments, and patient preferences. The identification of predictive biomarkers in response to TAS-102 or its toxicity is urgently needed for better patient selection. Moreover, to strengthen efficacy or relieve toxicity, combinations with other agents, which could potentially emerge as standard treatment regimens, have been investigated and compared to existing active regimens for mCRC. Dove Medical Press 2017-09-15 /pmc/articles/PMC5608085/ /pubmed/28979148 http://dx.doi.org/10.2147/OTT.S106101 Text en © 2017 Sunakawa et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Sunakawa, Yu
Izawa, Naoki
Mizukami, Takuro
Horie, Yoshiki
Hirakawa, Mami
Arai, Hiroyuki
Ogura, Takashi
Tsuda, Takashi
Nakajima, Takako Eguchi
Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy
title Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy
title_full Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy
title_fullStr Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy
title_full_unstemmed Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy
title_short Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy
title_sort profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608085/
https://www.ncbi.nlm.nih.gov/pubmed/28979148
http://dx.doi.org/10.2147/OTT.S106101
work_keys_str_mv AT sunakawayu profileoftrifluridinetipiracilhydrochlorideinthetreatmentofmetastaticcolorectalcancerefficacysafetyandplaceintherapy
AT izawanaoki profileoftrifluridinetipiracilhydrochlorideinthetreatmentofmetastaticcolorectalcancerefficacysafetyandplaceintherapy
AT mizukamitakuro profileoftrifluridinetipiracilhydrochlorideinthetreatmentofmetastaticcolorectalcancerefficacysafetyandplaceintherapy
AT horieyoshiki profileoftrifluridinetipiracilhydrochlorideinthetreatmentofmetastaticcolorectalcancerefficacysafetyandplaceintherapy
AT hirakawamami profileoftrifluridinetipiracilhydrochlorideinthetreatmentofmetastaticcolorectalcancerefficacysafetyandplaceintherapy
AT araihiroyuki profileoftrifluridinetipiracilhydrochlorideinthetreatmentofmetastaticcolorectalcancerefficacysafetyandplaceintherapy
AT oguratakashi profileoftrifluridinetipiracilhydrochlorideinthetreatmentofmetastaticcolorectalcancerefficacysafetyandplaceintherapy
AT tsudatakashi profileoftrifluridinetipiracilhydrochlorideinthetreatmentofmetastaticcolorectalcancerefficacysafetyandplaceintherapy
AT nakajimatakakoeguchi profileoftrifluridinetipiracilhydrochlorideinthetreatmentofmetastaticcolorectalcancerefficacysafetyandplaceintherapy